Inventor · disambiguated record
Timucin Avsar
Also filed as: AVSAR TIMUCIN
6 granted patents·4 pending applications·0 citations·filing 2021–2021
64Inventor score
Files withBAHCESEHIR UNIV10
Top patents by PatentIndex Score
10 records- 0156US12398128B2Physics-driven discovery of novel small therapeutic compounds for use as a BCL-2 inhibitorBAHCESEHIR UNIV·Filed 2021·Granted Aug 26, 2025·0 cites·6 claims
- 0256US12297175B2Physics-driven discovery of novel small therapeutic compounds for use as a BCL-2 inhibitorBAHCESEHIR UNIV·Filed 2021·Granted May 13, 2025·0 cites·20 claims
- 0355US12435074B2Physics-driven discovery of novel small therapeutic compounds for use as a BCL-2 inhibitorBAHCESEHIR UNIV·Filed 2021·Granted Oct 7, 2025·0 cites·15 claims
- 0451US12502392B2DRG-MDM2-6 for use as a novel mouse double minute 2 (MDM2) inhibitorBAHCESEHIR UNIV·Filed 2021·Granted Dec 23, 2025·0 cites·16 claims
- 0551US12318368B2Physics-driven discovery of novel small therapeutic compounds for use as a BCL-2 inhibitorBAHCESEHIR UNIV·Filed 2021·Granted Jun 3, 2025·0 cites·1 claims
- 0648US12384746B2Physics-driven discovery of novel small therapeutic compounds for use as a BCL-2 inhibitorBAHCESEHIR UNIV·Filed 2021·Granted Aug 12, 2025·0 cites·1 claims
- 0742US2024270730A1Drg-mdm2-2 for use as a novel mouse double minute 2 (mdm2) inhibitorBAHCESEHIR UNIV·Filed 2021·Application pending·0 cites
- 0842US2023071340A1Drg-mdm2-4 for use as a novel mouse double minute 2 (mdm2) inhibitorBAHCESEHIR UNIV·Filed 2021·Application pending·0 cites
- 0941US2023067644A1Drg-mdm2-3 for use as a novel mouse double minute 2 (mdm2) inhibitorBAHCESEHIR UNIV·Filed 2021·Application pending·0 cites
- 1040US2023063449A1Drg-mdm2-5 for use as a novel mouse double minute 2 (mdm2) inhibitorBAHCESEHIR UNIV·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Timucin Avsar files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →